CEO of FutureThink
Topic: Kill The Company: How Covid-19 Challenged the Status Quo and Reinvented How we Work
Unproductive meetings, endless emails, and reports-for-the-sake-of-reporting aren’t the definition of meaningful work—they’re the result of complexity. To create a workplace where there’s actually time and space to innovate, you’ll learn from CEO and TED-talk veteran Lisa Bodell how to become your own chief simplification officer. Get the techniques used by the nimblest of companies to save time, kill rules, and boost productivity on the work that matters. By killing complexity, you’ll increase customer trust, staff retention, and innovate faster.
FutureThink CEO Lisa Bodell is the bestselling author of Kill the Company and Why Simple Wins. She’s a global leader on simplification and innovation, whose keynotes leave audiences inspired to change and armed with radically simple tools to get to the work that matters.
Bodell brings a compelling perspective to the sought-after topics of simplification and innovation. Her transformational message has inspired executives at top-ranked organizations such as Google, Cisco, Citigroup, Merck, and the U.S. Navy War College.
Based on her best-selling book, WHY SIMPLE WINS: Escape the Complexity Trap and Get to the Work that Matters, Lisa’s keynotes offer tools and takeaways on how organizations and individuals can eradicate complexity and allow Simplicity to be their new operating system.
With a deep understanding of best practices across industries, Lisa Bodell has contributed her expertise to a wide variety of media, including: Fast Company, WIRED, The New York Times, Inc., Bloomberg Businessweek, Forbes, Harvard Business Review, The Huffington Post, FOX News, and CNN.
Bodell has taught innovation at both American University and Fordham University, and has a TED talk on the topic. She has served on the board of advisors of several organizations, including the Global Agenda Council for the World Economic Forum, the NSA, the Association of Professional Futurists, and Novartis